title: Plasma levels, safety, and 60-week efficacy of a once-daily double-boosted protease inhibitor regimen of atazanavir, saquinavir, and ritonavir.
authors.forename: Weerawat
authors.initials: W
authors.lastname: Manosuthi
authors.forename: Somnuek
authors.initials: S
authors.lastname: Sungkanuparph
authors.forename: Kiat
authors.initials: K
authors.lastname: Ruxrungtham
authors.forename: Wisit
authors.initials: W
authors.lastname: Prasithsirikul
authors.forename: Chatiya
authors.initials: C
authors.lastname: Athichathanabadi
authors.forename: Woraphot
authors.initials: W
authors.lastname: Tantisiriwat
authors.forename: Chureeratana
authors.initials: C
authors.lastname: Bowonwatanuwong
authors.forename: Nopphanath
authors.initials: N
authors.lastname: Chumpathat
authors.forename: Achara
authors.initials: A
authors.lastname: Chaovavanich
mesh_terms: D000069446:Atazanavir Sulfate; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D009842:Oligopeptides / Q000008:administration & dosage / Q000627:therapeutic use*; D011725:Pyridines / Q000008:administration & dosage / Q000627:therapeutic use*; D019438:Ritonavir / Q000008:administration & dosage / Q000627:therapeutic use*; D019258:Saquinavir / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D017320:HIV Protease Inhibitors; D009842:Oligopeptides; D011725:Pyridines; D000069446:Atazanavir Sulfate; D019258:Saquinavir; D019438:Ritonavir